Modern drugs, immunotherapy and biological agents are revolutionizing the treatment of lymphoproliferative disorders by improving the cure rates in many different settings, especially of relapsing/refractory diseases, and by reducing the toxicity profile compared to the standard chemotherapy regimen. Alongside the development of systemic regimens, we are facing significant improvements in radiotherapy. This is characterized by a reduction in treatment fields and doses and by continuous advancements in the precision of the delivery techniques, with the expectation of significantly reducing radiotherapy-related side effects, particularly in long-term survivors. The interest in the association of novel systemic agents and modern radiotherapy is mounting, with several prospective studies focused on this promising “combo-treatment” in different scenarios.
The aim of the Research Topic is to discuss the advances in multimodal treatment in lymphoma patients, with the goal of describing the feasibility and safety of novel drugs along with their actual limitations and potential side effects, presenting the potential of modern radiotherapy in improving the quality of treatment and reducing the side effects, and highlighting the biological and clinical rationale of an integrated approach of systemic agents with modern radiotherapy techniques in this setting. We welcome Original Research as well as Case Reports, Case series, Clinical Trials, Hypothesis and Theory, Review.
Potential topics for the Research Topic include, but are not limited to:
1) combination of novel drugs and radiotherapy in the treatment of lymphoma patients;
2) priming/bridging role of radiotherapy in patients undergoing CAR T-cell therapy;
3) bispecific antibodies and novel systemic drugs in the treatment of lymphoma patients;
4) adoption of novel drugs in the treatment of relapsed/refractory lymphomas;
5) adoption of modern radiotherapy techniques to improve the therapeutic index of hematological patients, with a particular focus on the reduction of acute and chronic side effects.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Modern drugs, immunotherapy and biological agents are revolutionizing the treatment of lymphoproliferative disorders by improving the cure rates in many different settings, especially of relapsing/refractory diseases, and by reducing the toxicity profile compared to the standard chemotherapy regimen. Alongside the development of systemic regimens, we are facing significant improvements in radiotherapy. This is characterized by a reduction in treatment fields and doses and by continuous advancements in the precision of the delivery techniques, with the expectation of significantly reducing radiotherapy-related side effects, particularly in long-term survivors. The interest in the association of novel systemic agents and modern radiotherapy is mounting, with several prospective studies focused on this promising “combo-treatment” in different scenarios.
The aim of the Research Topic is to discuss the advances in multimodal treatment in lymphoma patients, with the goal of describing the feasibility and safety of novel drugs along with their actual limitations and potential side effects, presenting the potential of modern radiotherapy in improving the quality of treatment and reducing the side effects, and highlighting the biological and clinical rationale of an integrated approach of systemic agents with modern radiotherapy techniques in this setting. We welcome Original Research as well as Case Reports, Case series, Clinical Trials, Hypothesis and Theory, Review.
Potential topics for the Research Topic include, but are not limited to:
1) combination of novel drugs and radiotherapy in the treatment of lymphoma patients;
2) priming/bridging role of radiotherapy in patients undergoing CAR T-cell therapy;
3) bispecific antibodies and novel systemic drugs in the treatment of lymphoma patients;
4) adoption of novel drugs in the treatment of relapsed/refractory lymphomas;
5) adoption of modern radiotherapy techniques to improve the therapeutic index of hematological patients, with a particular focus on the reduction of acute and chronic side effects.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
